Servier supports colorectal cancer screening
Initiated by the Digestive Cancers Europe (DiCE) patient organization, the campaign aims to encourage early diagnosis by improving colorectal cancer screening programs. It also seeks to increase available information on the disease and general awareness of it. This year, the campaign slogan, “This March, let’s move together to reduce the risk of colorectal cancer”, was co-developed by DiCE and Servier.
The absence of symptoms is common. Colorectal cancer can therefore develop silently and can remain undiagnosed for a while. This is why screening is necessary.
We are mobilizing worldwide through digital campaigns that resonate deeply with patients, aiming to raise awareness about this cancer, its risk factors, and its symptoms. For instance, our teams in Greece and Germany are spearheading social media awareness campaigns focused on the importance of screening. In Spain, Servier has launched ‘La Fuerza de Ser Únicos,’ an initiative leveraging social media influencers to emphasize holistic patient support through sports, nutrition, and emotional well-being, while honoring the uniqueness of every individual.
Colorectal cancer: Screening still comes too late
Colorectal cancer is a common disease. It is one of the most frequently diagnosed cancers in the world. Coming in third place behind lung and liver cancer, it affects almost as many women as men1.
A bold strategy for innovation in oncology
Our goal is to create precision therapies for patients living with rare forms of cancers with unmet medical needs. We are a focused and innovative player in the treatment of digestive cancers (colorectal cancer, gastric cancer, pancreatic cancer, cholangiocarcinoma), brain tumors (glioma), and hematologic cancers (acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma). In response to the growing need for therapeutic solutions, we dedicate nearly 70% of our R&D budget to oncology.
We draw on precision medicine, underpinned in particular by companion diagnostic tests2. This breakthrough innovation enables us to develop treatments that target cancer types with high unmet medical needs.
Acting with and for patients in the area of colorectal cancer
PROMETCO is the first real-world evidence study in oncology conducted by our teams that is specifically focused on metastatic colorectal cancer. Developed jointly with the non-profit patient organization DiCE, PROMETCO gives us a more accurate picture of metastatic colorectal cancer management from the perspective of both patients and physicians.
PROMETCO keeps patients actively involved throughout the study process, not only in data collection, but also in design and dissemination of results. The data collected includes information on quality of life, such as mobility, personal care, daily activities, pain and discomfort, anxiety and depression, in addition to long-term treatment adherence and the impact the disease has on daily life. These are key factors for both patients and doctors.
Our actions in conjunction with the patient organization DiCE continue through the international program SHAPE (Support Harmonized Advances for better Patient Experiences). This initiative consists in providing patient support through various means, including brochures designed in collaboration with patient advocates. These brochures cover the crucial aspects of living day-to-day with the disease and include numerous tips.
[1] OMS – Fact Sheet – Cancer – https://www.who.int/fr/news-room/fact-sheets/detail/cancer#:~:text=le%20cancer%20colorectal%20(916%20000,sein%20(685%20000%20d%C3%A9c%C3%A8s)., consulted in March 2026
[2] A companion diagnostic test is designed to determine which subpopulation of patients are likely to respond favorably to a given treatment by identifying markers that predict treatment response in patients.